- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Real-world evidence, Real-world effectiveness, Real-world: LURBICLIN: RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (clinicaltrials.gov) - Jun 30, 2022 P=N/A, N=200, Recruiting, Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024 Not yet recruiting --> Recruiting
- |||||||||| Pozenveo (poziotinib) / Assertio
Trial primary completion date, EGFR exon 20, HER2 exon 20, Metastases: NCI-2017-00831: Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC (clinicaltrials.gov) - Jun 27, 2022 P2, N=80, Recruiting, Not yet recruiting --> Recruiting Trial primary completion date: Mar 2022 --> Mar 2023
- |||||||||| Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer (Exhibit Hall - Hall B) - Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1109;
In our stage IV NSCLC population, there was no significant safety signal with sequential treatment of ICI followed by TKI; only one patient required treatment break/discontinuation due to pneumonitis. This differs from existing literature possibly because the majority of our population did not harbour a driver mutation and there were limited patients treated with crizotinib, ceritinib and osimertinib, other agents that have been associated with this safety signal.
- |||||||||| Pozenveo (poziotinib) / Assertio
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, HER2 exon 20, Metastases: A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies (clinicaltrials.gov) - Jun 14, 2022 P2, N=1, Terminated, When there is not enough tissue for molecular testing, plasma-based NGS can guide first-line treatment decisions in metastatic NSCLC and increase access to targeted therapy, which may lead to prolonged survival. N=150 --> 1 | Trial completion date: Dec 2023 --> Mar 2022 | Recruiting --> Terminated | Trial primary completion date: Jun 2023 --> Mar 2022; Strategic business decision (unrelated to safety)
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz, Tecentriq (atezolizumab) / Roche
Tincture of Time (Main Room) - May 25, 2022 - Abstract #Macula2022Macula_17; The offending drug was atezolizumab (Tecentriq), a humanized IgG1 monoclonal antibody targeted against programmed cell death ligand 1 (PD-L1)...From a systemic standpoint, her metastatic CCS has continued to respond to combination treatment on clinical trial with lurbinectedin/irinotecan...This case underscores the importance of recognizing the full spectrum of checkpoint inhibitor-associated ocular ir-AEs. Objective: To describe the long-term clinical findings and visual prognosis in a rare form of checkpoint inhibitor-associated retinopathy.
- |||||||||| Journal: The 2021 Marine Pharmacology and Pharmaceuticals Pipeline. (Pubmed Central) - May 14, 2022
In 2021, new marine-derived drugs were approved by FDA, as well as in Australia and China. The clinical development of marine-derived drugs remained very robust and active with several advancing to Ph III, Ph II and entering at Ph I.
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations (clinicaltrials.gov) - May 12, 2022 P2, N=19, Not yet recruiting, The clinical development of marine-derived drugs remained very robust and active with several advancing to Ph III, Ph II and entering at Ph I. Trial completion date: Mar 2026 --> Aug 2026 | Initiation date: Mar 2022 --> Aug 2022 | Trial primary completion date: Mar 2025 --> Aug 2025
|